Amarin Corp Plc (AMRN)

[ziploc_1]

RMB...IMHO The cognitive performance will be the most critical part of the study between the EPA group and the placebo group and this will determine the success or failure of the study.

QUOTE..."The proposed study aims to: 1) investigate the effects of 18 months of IPE vs. placebo on regional cerebral blood flow as measured by arterial spin-labeling MRI; 2) determine the impact of 18 months of IPE vs. placebo on CSF biomarkers of AD pathology; and 3) EVALUATE THE EFFECTS OF18 MONTHS OF of IPE vs. PLACEBO on COGNITIVE PERFORMANCE."

I would be surprised if there were changes in the MRI or CSF... as these come later after the disease is well established due to inflammation in the brain....and this is where Vascepa can help.